Celldex Therapeutics, Inc. (CLDX) Stock

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. (CLDX) stock trades at $29.25 with a market capitalization of $2.30B. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.26, reflecting a net loss over the last twelve months, price-to-book of 3.45, price-to-sales of 18803.06. Over the past 52 weeks the stock has ranged between $22.10 and $45.14, and currently trades 35.2% below its 52-week high.

On profitability, Celldex Therapeutics, Inc. generates a return on equity (ROE) of -52.36% (negative, reflecting a net loss), return on capital employed of -45.19%, an operating margin of -14350.00%, a net profit margin of -345.96%.

Celldex Therapeutics, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Celldex Therapeutics, Inc. reported revenue of $7.0M rising to $2.0M, a change of -71.4% across 10 years. Compounded, revenue has grown -22.2% a year over five years, 0.0% over three, -71.4% over the last twelve months. Net profit fell to $-259.0M.

Operating margin went from -1958.7% in 2016 to -19160.0% in 2025, a fall of 17201.3 percentage points. The most recent net margin is -345.96%. On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-301.0M.

Borrowings stand at $2.0M, cash from operations was $-211.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -30.9% over five years, and was -49.1% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Celldex Therapeutics, Inc. (CLDX) — frequently asked questions